Explore

Program Map

Start with a treatment, device, company, diagnosis, or trial ID. Each record keeps the source trail close to the claim.

161Main(26 active)

148Status checked

135Strong

320Backlog

More filters and sort (2 active)

Company-led only

2 records in Main database · 2 strong · 2 status checked

Compare	Program	Company	Type	Product	Modality	Stage	Status	Reliability	Evidence	Conf.	Population	Indications	Inspect
Add	AK-OTOF by Eli Lilly and Akouos	Eli Lilly and Company	Therapeutic	-	Gene Therapy	Phase 2	Active	Details checkedStrong evidence	trial · Priority 1	95%	PediatricAdult+6	Hearing LossSensorineural Hearing Loss+3
Add	AK-antiVEGF by Eli Lilly and Akouos	Eli Lilly and Company	Therapeutic	-	Gene Therapy	Phase 1/2	Active	Details checkedStrong evidence	trial · Priority 2	90%	AdultUnilateral+2	Vestibular SchwannomaHearing Loss